Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 482-020-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
A full OECD guideline 417 toxicokinetics study in rats is available for this substance.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 93.5
- Absorption rate - dermal (%):
- 20
- Absorption rate - inhalation (%):
- 100
Additional information
An OECD 417 guideline oral rat ADME study is available for this substance. The results are summarised as follows:
Absorption: The percent absorption of the orally administered dose in the low and high dose groups was at least 92-95%, based on recovery in urine and non-GI tissues for either dose level. Based on this high level of oral absorption, it is assumed that absorption via the inhalation route will be similar.
The dermal penetration of 1, 3 - and 1, 4 -cyclohexanedicarboxaldehyde was estimated using the DERMWIN module of EPI Suite. The estimated dermal permeability (Kp) is 0.00124cm/h for both isomers, indicating that Unoxol dialdehyde is has a potential for dermal absorption. Based on the QSAR dermal prediction estimate via flux values proposed by Moster and Goergens (Mostert and Goergens, 2011), the dermal absorption for Unoxol is estimated as 20% per 8-hr shift.
Distribution: Similar pharmacokinetic parameters were observed in rats for either dose level. The time-course of 14C-1,3- and 1,4-CHDA-derived radioactivity in plasma exhibited a biphasic decline after reaching Cmax and was therefore fit to a two-compartment pharmacokinetic model. Plasma radioactivity declined rapidly during the alpha phase (t½α = ~1.8-3 hours), followed by a slower decline during the terminal beta phase (t½beta = ~6 hours).
Metabolism and Elimination: The reaction mixture was widely metabolized and no parent 1,3 -CHDA and 1,4 -CHDA were detected in the urine and fecal samples. A total of 11 radiochemical peaks were detected in the acidified urine and/or fecal samples across the profiles of all dose levels. Only five major peaks (containing six major metabolites) of the 11 radiochemical peaks accounted for more than 5% of the administered dose. Of these five peaks, two (39 to 45% and 9% of the administered dose respectively), were identified as the cis and trans isomers of 1,3-cyclohexanedicarboxylic acid (1,3-CHD acid) (isomer assignments unknown). Two peaks (17% and 10 -12% of the administered dose respectively) were identified as the cis and trans isomers of 1,4-cyclohexanedicarboxylic acid (1,4-CHD acid) (isomer assignments unknown). Two additional major peaks were tentatively identified as either the cis or trans isomer of 4-(hydroxymethyl)cyclohexanecarboxylic acid (Peak C), which comprised ~7 % to 11 % of the administered dose, and either the cis or trans isomer of 3-(hydroxymethyl)¬cyclohexane carboxylic acid (Peak D-2) which comprised ~9 % of the administered dose The majority (91-94%) of the administered 14C-1,3- and 1,4-CHDA derived radioactivity was rapidly excreted in urine without any difference between the dose levels. The majority of the urinary elimination (91-95%) occurred within the first 12 hours post-dosing. Most of the remaining oral dose (9-13%) was eliminated in feces, with the majority of the fecal elimination (80-91%) occurring within the first 24 hours post-dosing.
Bioaccumulation potential: Less than 0.06% of the orally administered 14C-1,3- and 1,4-CHDA remained in the tissues after 168 hours (7 days) post-dosing in all of the groups, indicating the very low bioaccumulation potential 14C-1,3- and 1,4-CHDA in rats.
Reference
Mostert, V., and A. Goergens. 2011. Dermal DNEL setting: Using QSAR predictions for dermal absorption for a refined route-to-route extrapolation.NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 383:90.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
